⚖️ Disclaimer: This podcast is for informational purposes only and does not constitute investment advice or a solicitation to invest. Invst Guru is not affiliated with Berkshire Biomedical, StartEngine, or any broker-dealer. Any investments under Regulation Crowdfunding must be made through a registered intermediary platform. No investment terms are discussed or offered in this episode. For full offering details, including risks and disclosures, visit the official Berkshire Biomedical campaign page on StartEngine.

In this spotlight episode, we explore Berkshire Biomedical, a pioneering Dallas-based medtech company reimagining outpatient care for patients struggling with Opioid Use Disorder (OUD).

You'll learn how their flagship product, COPA™ (Controlled Oral Prescription Administration), combines fingerprint and dentition biometrics with real-time remote monitoring to create a new model for secure, at-home medication management.

We also dive into:

• The massive unmet need in OUD treatment
• The healthcare trends supporting at-home care innovation
• The company's milestones, including NIH funding and FDA pre-submission progress
• Key risks and challenges facing any early-stage healthtech company

Berkshire Biomedical is on a mission to expand treatment access while maintaining accountability and security. Their story offers an inside look at how mission-driven technology can intersect with pressing social needs.

🔗 Learn more about Berkshire Biomedical and review their official Reg CF campaign documents here.

Hosted on Acast. See acast.com/privacy for more information.